ArticleGene therapy2000
In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- Antiviral Immune Responses Against Murine Cytomegalovirus Induced by an OralMicroorganisms · 2025Article
- Amelioration of Murine Colitis by AttenuatedMicroorganisms · 2023Article
- Bacterially Delivered miRNA-Mediated Toll-like Receptor 8 Gene Silencing for Combined Therapy in a Murine Model of Atopic Dermatitis: Therapeutic Effect of miRTLR8 in AD.Microorganisms · 2021Article
- Article
- Article
- Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.Viruses · 2013Review
- Inhibition of hepatitis B virus gene expression and replication by ribonuclease P.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.Gene therapy · 2013Article
- Article
- Effective inhibition of cytomegalovirus infection by external guide sequences in mice.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Suppression of inflammation by recombinant Salmonella typhimurium harboring CCL22 microRNA.DNA and cell biology · 2012Article
- Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Salmonella-mediated delivery of RNase P-based ribozymes for inhibition of viral gene expression and replication in human cells.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- High-throughput screening for salmonella avirulent mutants that retain targeting of solid tumors.Cancer research · 2010Article
- Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.Infection and immunity · 2008Article
- Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain.Infection and immunity · 2007Article
- Bacteria in gene therapy: bactofection versus alternative gene therapy.Gene therapy · 2006Review
- Bacterial transfer of large functional genomic DNA into human cells.Gene therapy · 2005Article
- Engineered E. coli delivers therapeutic genes to the colonic mucosa.Gene therapy · 2005Article
- DNA modification and functional delivery into human cells using Escherichia coli DH10B.Nucleic acids research · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Macrophages are normal targets for Salmonella during natural infections, and it has been demonstrated that attenuated bacteria can deliver nucleic acid vaccine constructs. Therefore, we assessed if attenuated Salmonella can be used for the in vivo delivery of transgenes to their natural cellular target, in an attempt to correct genetic defects associated with monocytes/macrophages. This system would offer the distinct advantage of achieving a specific targeting of defective cells in a non-invasive form. Using a reporter gene, we demonstrated that attenuated Salmonella could be used as an effective in vitro delivery system to transfer genetic material into nondividing cells like murine macrophages. In vivo, the oral administration of attenuated Salmonella allows targeted delivery of transgenes to macrophages and subsequently expression of transgenes at a systemic level. IFNgamma-deficient mice (GKO) were thus selected as a model for the in vivo validation of the Salmonella-based delivery approach. Attenuated Salmonella, used as the carrier for a eukaryotic expression vector encoding the murine IFNgamma gene, was able to restore the production of this cytokine in GKO macrophages. Their oral administration to IFNgamma-deficient mice also re-established, in these immunocompromised animals, the natural resistance to bacterial infections. These results demonstrate, for the first time, that attenuated Salmonella can be successfully used in vivo as a DNA delivery system for the correction of a genetic defect associated with monocyte/macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.